← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
E7777 (E7777)
Eisai Inc.·DLBCL
7 trials
Overview
Program
E7777
Overview
Company
Eisai Inc.
Overview
Modality
CGT
Overview
Target
DLBCL
Overview
Indication
DLBCL; Diffuse Large B Cell Lymphoma
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Clinically approved immunotoxins targeting hematological cancers: "the best of both worlds".. Hematological malignancies contribute significantly to the overall cancer burden. Certain subtypes, such as hairy cell leukemia (HCL), are chronic and characterized by residual disease after first-line therapy, while others, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), are aggressive and …
Clinical
Safety signal
Clinically approved immunotoxins targeting hematological cancers: "the best of both worlds".. Hematological malignancies contribute significantly to the overall cancer burden. Certain subtypes, such as hairy cell leukemia (HCL), are chronic and characterized by residual disease after first-line therapy, while others, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), are aggressive and …
Clinical
Selected reported efficacy
ORR 41.2%
Clinical
Reported ORR
41.2%
Clinical
Result source
ClinicalTrials.gov NCT02676778
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT02676778